White Elm Capital Has Decreased Synchrony Finl (SYF) Position; Amicus Therapeutics (FOLD)’s Sentiment Is 1.23

November 14, 2017 - By Darrin Black

White Elm Capital Llc decreased Synchrony Finl (SYF) stake by 1.23% reported in 2017Q2 SEC filing. White Elm Capital Llc sold 11,600 shares as Synchrony Finl (SYF)’s stock declined 26.83%. The White Elm Capital Llc holds 931,400 shares with $27.77M value, down from 943,000 last quarter. Synchrony Finl now has $25.40 billion valuation. The stock declined 0.40% or $0.13 reaching $32.46 per share. About 2.10 million shares traded. Synchrony Financial (NYSE:SYF) has declined 10.35% since November 14, 2016 and is downtrending. It has underperformed by 27.05% the S&P500.

Amicus Therapeutics, Inc. is a biotechnology company. The company has market cap of $2.07 billion. The Firm is engaged in the discovery, development and commercialization of a set of treatments for patients living with devastating rare and orphan diseases. It currently has negative earnings. The Company’s lead product, migalastat HCl is a small molecule that can be used as a monotherapy and in combination with enzyme replacement therapy for Fabry disease.

Among 27 analysts covering Synchrony Financial (NYSE:SYF), 19 have Buy rating, 0 Sell and 8 Hold. Therefore 70% are positive. Synchrony Financial had 57 analyst reports since July 20, 2015 according to SRatingsIntel. As per Monday, July 17, the company rating was maintained by BTIG Research. The firm earned “Neutral” rating on Thursday, September 10 by Sterne Agee CRT. The stock of Synchrony Financial (NYSE:SYF) has “Hold” rating given on Tuesday, October 10 by Wells Fargo. The firm earned “Buy” rating on Wednesday, May 4 by Deutsche Bank. The rating was downgraded by Bank of America to “Hold” on Friday, October 6. BTIG Research maintained the shares of SYF in report on Thursday, May 25 with “Buy” rating. The company was maintained on Monday, October 19 by BMO Capital Markets. The firm has “Buy” rating by Jefferies given on Monday, September 18. The rating was maintained by Morgan Stanley with “Overweight” on Tuesday, July 25. Keefe Bruyette & Woods maintained Synchrony Financial (NYSE:SYF) rating on Thursday, June 15. Keefe Bruyette & Woods has “Buy” rating and $3900 target.

Analysts await Synchrony Financial (NYSE:SYF) to report earnings on January, 19. They expect $0.68 EPS, down 2.86% or $0.02 from last year’s $0.7 per share. SYF’s profit will be $532.10M for 11.93 P/E if the $0.68 EPS becomes a reality. After $0.70 actual EPS reported by Synchrony Financial for the previous quarter, Wall Street now forecasts -2.86% negative EPS growth.

About 1.30 million shares traded. Amicus Therapeutics, Inc. (FOLD) has risen 12.45% since November 14, 2016 and is uptrending. It has underperformed by 4.25% the S&P500.

Analysts await Amicus Therapeutics, Inc. (NASDAQ:FOLD) to report earnings on March, 7. They expect $-0.28 earnings per share, up 12.50% or $0.04 from last year’s $-0.32 per share. After $-0.41 actual earnings per share reported by Amicus Therapeutics, Inc. for the previous quarter, Wall Street now forecasts -31.71% EPS growth.

Since January 1, 0001, it had 0 insider buys, and 2 insider sales for $539,312 activity.

Perceptive Advisors Llc holds 8.76% of its portfolio in Amicus Therapeutics, Inc. for 17.30 million shares. Venbio Select Advisor Llc owns 5.93 million shares or 7.54% of their US portfolio. Moreover, Redmile Group Llc has 7.38% invested in the company for 12.04 million shares. The Quebec – Canada-based Sectoral Asset Management Inc has invested 3.84% in the stock. Palo Alto Investors Llc, a California-based fund reported 7.94 million shares.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:


Recent Market News

>